Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer

Inclusion Criteria:

Histologically confirmed metastatic adenocarcinoma of the lung
Patients must have received and completed first line therapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1
No external beam radiation therapy within 2 weeks of first vaccine administration
No stereotactic radiation therapy within 3 days of first vaccine
No targeted therapy within 2 weeks of first vaccine administration
No immunomodulatory therapy within 2 weeks of first vaccine administration
No chemotherapy within 4 weeks of first vaccine administration
During Screening period, no steroid therapy within 4 weeks of first vaccine administration
Patient's written informed consent

Adequate organ function (measured within a week of beginning treatment):

White blood count (WBC) > 3,000/mm³ and absolute neutrophil count (ANC) >/= 1500/mm³
Platelets > 100,000/mm³
Hematocrit > 25%
Bilirubin < 2.0 mg/dL
Creatinine < 2.0 mg/dL, or creatinine clearance > 60 mL/min
Patients will be tested for HLA-A0201 as determined by flow cytometry followed by molecular analysis of a peripheral blood specimen; however this result will not be an inclusion criterion.
Measurable metastatic tumor as defined by standard Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Lesions must be accurately measured in at least one dimension with the longest diameter ≥20 mm. With spiral computed tomography (CT) scan, lesion must be ≥10 mm in at least one dimension.

Exclusion Criteria:

Symptomatic brain metastasis or Uncontrolled central nervous system (CNS) metastasis will not be permitted.
Any acute medical problems requiring active intervention
Current corticosteroid (other than replacement doses in patients who are hypo-adrenal) or other immunosuppressive therapy
Any other pre-existing immunodeficiency condition (including known human immunodeficiency virus [HIV] infection)
Any known pre-existing autoimmune disorder
History of a second malignancy within the previous 2 years (except non-melanoma skin cancer and cervical in-situ)
Patients who have had major surgery without full recovery or major surgery within three weeks of the start of vaccine treatment
Pregnant or lactating women: Patients in reproductive age must agree to use contraceptive methods for the duration of the study (*A pregnancy test will be obtained before treatment).
Eastern Cooperative Oncology Group (ECOG) performance status of 2, 3, or 4
Patients with other significant diseases or disorders that, in the Investigator's opinion, would exclude them from the study.
Patients who at the discretion of the investigator are deemed to have rapidly progressive disease